Invivo Therapeutics Holdings Corp. (OTCBB: NVIV) is a development stage company engaged in the development and commercialization of biopolymer scaffolding devices for the treatment of spinal cord injuries, peripheral nerve injuries, and other neurotrauma conditions. The company also aims to develop and commercialize biocompatible hydrogel for use as dural sealants and replacements and nerve conduits and for local controlled release of methylprednisolone to treat spinal cord injuries and peripheral nerve injuries. For more information, visit the company’s website at www.invivotherapeutics.com.